FINWIRES · TerminalLIVE
FINWIRES

NZE:AFT

11 stories mentioning NZE:AFTUpdated 2d ago

Every FINWIRES story that references NZE:AFT, newest first.

Asia

AFT Pharmaceuticals Says R&D Portfolio Targeting Multi-Billion-Dollar Market Potential

AFT Pharmaceuticals' (NZE:AFT, ASX:AFP) research and development portfolio is targeting a market potential in excess of $15 billion as the company works to strengthen its international operations, according to a Tuesday filing with the Australian and New Zealand bourses.The portfolio now covers eight patented projects, 24 off-patent injectables, and a range of projects in the early stages of commercialization, per the filing.The company is developing its business hubs in Australia, New Zealand, Singapore, Hong Kong, US, Canada, and the UK. This will allow certain parts of AFT's portfolio "to cover up to 50% of the global market directly," the company said.AFT's portfolio includes an intravenous iron therapy targeting a market as large as $7.4 billion, a room-temperature stable cream with a potential market greater than $1 billion, a medicine storage technology for which the market is estimated at up to $6 billion, and an infantile haemangioma medicine with a potential market in excess of $1 billion.In accompanying presentation materials, AFT Pharmaceuticals said it is targeting fiscal 2027 revenue of over NZ$300 million.The company's New Zealand-listed shares were up nearly 1% in recent Tuesday trade.

ASX:AFPNZE:AFT
Asia

AFT Pharmaceuticals Offers an Attractive Risk-Reward Profile With an Expanding Clinical Pipeline, Pitt Street Research Says

AFT Pharmaceuticals (ASX:AFP, NZE:AFT) represented an attractive risk-reward profile for equity investors given the company's two-decade growth record, active US commercialization, and expanding international pipeline, Pitt Street Research said in a Friday note.The specialty pharmaceutical company offers "significant upside" from a pipeline of new commercial opportunities that is being overlooked by the market, the equity research firm said.It pointed to Combogesic as one of the company's most commercially significant assets, noting that the painkiller has secured a Medicare HCPCS J-code in the US and a national shelf presence through an agreement with Cost Plus Drugs.Pitt Street values AFT Pharmaceuticals at AU$10.55 per share in a base case and AU$13.08 per share in a bull scenario, with its models showing at least AU$600 million of value to be unlocked in AFT's pipeline.The company closed nine licensing agreements in fiscal 2026 and guided for fiscal year 2027 research and development investment of NZ$25 million, "suggesting a pipeline that is being actively monetized rather than held speculatively," Pitt Street said.It added that AFT Pharmaceuticals increased its revenue every year for nearly two decades in "a record that is genuinely rare among ASX-listed healthcare companies of any size."AFT Pharmaceuticals' Australian shares gained 4% in recent Friday trade, while its New Zealand shares climbed 6%.

ASX:AFPNZE:AFT
Asia

New Zealand Shares Fall; Contact Energy Posts Higher Retail Electricity, Gas Sales in June

New Zealand shares ended lower on Tuesday as investors braced for a possible intensified US-Iran conflict after the Iran-aligned Houthis said they would impose a naval blockade on Saudi Arabia.The S&P/NZX 50 Index fell 0.29% or 40 points to close at 13,656.03.The Houthis, Yemen's Iran-backed militant group, announced a naval blockade of Saudi Arabia on Monday, a move that risks drawing Riyadh into the broader US-Iran conflict and adding further pressure on global energy markets and shipping lanes, according to a Monday Reuters report.New Zealand and the Philippines have established a comprehensive partnership, New Zealand Foreign Minister Winston Peters said on Tuesday, according to a Tuesday Reuters report.In domestic news, New Zealand's annual consumer inflation increased by 4.1% in the June quarter, up from a 3.1% increase in the 12 months to the March quarter, data from Stats NZ showed.Further, the signal on underlying inflation in New Zealand's June quarter consumer price index (CPI) data was mixed and isn't likely to budge the Reserve Bank of New Zealand (RBNZ) from its policy stance, with the trimmed mean and weighted median measures accelerating, but the ex-fuel and energy measure slowing, ANZ said in a note.In corporate news, Contact Energy (ASX:CEN, NZE:CEN) said retail mass-market electricity and gas sales increased year-on-year in June, alongside a rise in wholesale contracted electricity sales.AFT Pharmaceuticals' (ASX:AFP, NZE:AFT) Scomara topical cream intended for the treatment of facial angiofibromas in tuberous sclerosis received a tentative approval from the US Food and Drug Administration.

^NZ50ASX:AFPASX:CENNZE:AFTNZE:CEN
Asia

AFT Pharmaceuticals' Topical Cream Secures Tentative US FDA Approval

AFT Pharmaceuticals' (ASX:AFP, NZE:AFT) Scomara topical cream intended for the treatment of facial angiofibromas in tuberous sclerosis received a tentative approval from the US Food and Drug Administration (FDA), according to a Tuesday filing with the Australian bourse.The quality, efficacy, and safety data have been evaluated, leading to tentative approval of the product labeling and claims, the filing said.However, launch and commercialization are subject to existing "orphan exclusivity" for another product that was granted in 2022 and expires on March 22, 2029, per the filing.

ASX:AFPNZE:AFT
Asia

NZX Biggest Gainers

Here are the NZX-listed companies with the biggest gains on Wednesday.Synlait Milk (NZE:SML): +4%, NZ$0.43Steel & Tube Holdings (NZE:STU): +3%, NZ$0.36New Zealand King Salmon (NZE:NZK): +2%, NZ$0.23Napier Port Holdings (NZE:NPH): +2%, NZ$3.70AFT Pharmaceuticals (NZE:AFT): +2%, NZ$3.78Ventia Services Group (NZE:VNT): +2%, NZ$8.40Investore Property (NZE:IPL): +1%, NZ$1.05Channel Infrastructure NZ (NZE:CHI): +1%, NZ$3.20T&G Global (NZE:TGG): +1%, NZ$2.45Air New Zealand (NZE:AIR): +1%, NZ$0.46

^NZ50NZE:AFTNZE:AIRNZE:CHINZE:IPLNZE:NPHNZE:NZKNZE:SMLNZE:STUNZE:TGGNZE:VNT
Asia

AFT Pharmaceuticals Gets US FDA Nod for Phase 3 Trial of Injectable Iron Therapy

AFT Pharmaceuticals (NZE:AFT, ASX:AFP) said the US Food and Drug Administration allowed the company to proceed with a phase 3 clinical trial of its injectable iron deficiency therapy, according to a Wednesday filing with the Australian and New Zealand bourses.AFT and development partner Hyloris Pharmaceuticals plan to launch a global confirmatory study involving 1,366 patients across multiple geographies including New Zealand, China, India, Japan, Armenia, Europe, and the US.The therapy targets an addressable market estimated at $7.41 billion, per the filing.The company's New Zealand shares gained 2% in recent Wednesday trade.

ASX:AFPNZE:AFT
Asia

NZX Biggest Losers

Here are the NZX-listed companies with the biggest losses on Friday.Manuka Resources (NZE:MKR): -8%, NZ$0.10Black Pearl Group (NZE:BPG): -2%, NZ$0.62The Warehouse Group (NZE:WHS): -2%, NZ$0.62Gentrack Group (NZE:GTK): -2%, NZ$3.75Pacific Edge (NZE:PEB): -2%, NZ$0.30Hallenstein Glasson Holdings (NZE:HLG): -1%, NZ$10.01AFT Pharmaceuticals (NZE:AFT): -1%, NZ$3.88Air New Zealand (NZE:AIR): -1%, NZ$0.41SkyCity Entertainment Group (NZE:SKC): -1%, NZ$0.46PGG Wrightson (NZE:PGW): -1%, NZ$2.08

^NZ50NZE:AFTNZE:AIRNZE:BPGNZE:GTKNZE:HLGNZE:MKRNZE:PEBNZE:PGWNZE:SKCNZE:WHS
Asia

Update: AFT Pharmaceuticals Posts Higher Fiscal 2026 Earnings, Revenue; Shares Reach Three-Year High

(Update to add stock movement in the headline and fifth paragraph)AFT Pharmaceuticals (ASX:AFP, NZE:AFT) reported Thursday fiscal 2026 earnings of NZ$0.14 per share, up from NZ$0.11 a year earlier.Revenue for the 12 months ended March 31 was NZ$254.7 million, compared with NZ$208 million a year earlier.The company expects to continue its growth trajectory in fiscal 2027 as it works toward achieving its revenue target of at least NZ$300 million, with operating profit projected to range between NZ$28 million and NZ$32 million.The board declared a final dividend of NZ$0.025 per share, up from NZ$0.018 a year earlier, payable July 3 to shareholders on record as of June 19.Its shares rose over 11% in recent trading on the Australian bourse and over 9% on the New Zealand bourse, reaching an over three-year high.

ASX:AFPNZE:AFT
Asia

AFT Pharmaceuticals Posts Higher Fiscal 2026 Earnings, Revenue

AFT Pharmaceuticals (ASX:AFP, NZE:AFT) reported Thursday fiscal 2026 earnings of NZ$0.14 per share, up from NZ$0.11 a year earlier.Revenue for the 12 months ended March 31 was NZ$254.7 million, compared with NZ$208 million a year earlier.The company expects to continue its growth trajectory in fiscal 2027 as it works toward achieving its revenue target of at least NZ$300 million, with operating profit projected to range between NZ$28 million and NZ$32 million.The board declared a final dividend of NZ$0.025 per share, up from NZ$0.018 a year earlier, payable July 3 to shareholders on record as of June 19.

ASX:AFPNZE:AFT
Asia

New Zealand Shares Fall; AFT Pharmaceuticals Appoints CFO

New Zealand shares ended lower on Monday as all Asian shares saw losses after fresh drone attacks in the Gulf region.The S&P/NZX 50 Index fell 1.56% or 202.09 points to close at 12,762.92.A drone strike caused a fire in a nuclear power plant in the United Arab Emirates on Sunday, while Saudi Arabia said it intercepted three drones, according to a Sunday report by Reuters.In domestic news, New Zealand's services sector showed a modest improvement in April but remained in contraction, with persistent cost pressures and global shipping disruptions continuing to weigh on sentiment, according to a statement by BusinessNZ.In corporate news, AFT Pharmaceuticals (ASX:AFP, NZE:AFT) appointed Stuart Houliston as chief financial officer, effective June 15.Gentrack Group (NZE:GTK, ASX:GTK) acquired New Zealand software-as-a-service company Prospero Energy, trading as Factor, in a deal valued at NZ$24 million.

^NZ50ASX:AFPASX:GTKNZE:AFTNZE:GTK
Asia

AFT Pharmaceuticals Appoints CFO

AFT Pharmaceuticals (ASX:AFP, NZE:AFT) appointed Stuart Houliston as chief financial officer, effective June 15, according to a Monday filing with the Australian and New Zealand bourses.Houliston will succeed Malcolm Tubby after his retirement on May 29, with Simon Bosley taking on the role in the interim period, per the filing.Houliston will be joining the company from Sanford (NZE:SAN), the filing added.

ASX:AFPNZE:AFTNZE:SAN

Track with the FINWIRES app suite

FolioX
FolioX
Track NZE:AFT in your portfolio
WheelAI
WheelAI
Analyze NZE:AFT options with the wheel strategy
StockInsider
StockInsider
See market sentiment on NZE:AFT